New York, NY, United States
New York, NY, United States

Time filter

Source Type

News Article | December 7, 2016
Site: www.prnewswire.com

NEW YORK, Dec. 7, 2016 /PRNewswire/ -- Novus, the world's leading portfolio intelligence system for institutional investors, has been honored with a Glassdoor Employees' Choice Award, recognizing the Best Places to Work in 2017. The Employees' Choice Awards program, now in its ninth year,...


News Article | November 28, 2016
Site: www.prweb.com

Vancouver telecommunications company, Novus Entertainment Inc., recently launched its Ericsson Mediaroom-powered end-to-end IPTV service and selected Inca Networks’ high-density 4430 series modular MPEG-4 transcoders to provide video transcoding, processing, and monitoring for the full channel line-up. With a powerful and extensible architecture, the 4430 protects Novus’ investment with the ability to add 4K and next-generation HEVC codec support. Available in 2017, a forthcoming module for the 4430 transcoder chassis will deliver HEVC compression and new ultra-high-definition (UHD) 4K support. The deep visibility and extensive monitoring provided by the Inca VidiOS management platform, included in all Inca products, enables Novus to launch their new IPTV service while improving system visibility, lowering operating expenses, and lowering engineering costs. Novus leverages Inca’s class-leading density and low power consumption to transcode and process up to 36 HD or 90 SD channels in one rack unit of space. The 4430 also supports Mediaroom picture-in-picture (PIP) requirements and high-density audio transcoding. As a member of the Canadian Cable Systems Alliance, Novus has been one of the driving forces behind regulatory changes in Canada, to provide more affordable and flexible television options to the Canadian consumer. Their new IPTV service will continue to allow them to compete with larger Canadian telecommunications companies - with a focus on customer service. “We understand that video is a complex business for independent telecom operators. At Inca, we believe that head-end equipment should do more than just process video,” says Jeff Campbell, CEO of Inca Networks. “Transcoders should provide a deep and powerful set of tools to help independent operators run their video business and save money on a day-to-day basis. Deeper visibility and better control are the cornerstones of our VidiOS powered Intelligent Video Delivery solutions.” One of the key factors in Novus choosing Inca was the tight VidiOS integration between the Inca 4430 transcoder of the Inca 5420 All Seeing Eye (ASE) monitoring and management platform. The All Seeing Eye provides Novus with an innovative mosaic and visual monitoring of all IP video streams in their headend by leveraging the embedded monitoring capabilities present in every Inca product. The ASE also supports the monitoring of streams generated by other vendor’s equipment, to provide a true network-wide view of all video streams. Using the ASE allows any member of the Novus team to monitor the network using a simple web browser. The system also sends out email notifications when alarms are reported and when issues are resolved. With the launch of their new IPTV service, Novus is bringing Metro Vancouver residents a new, user-friendly interface for their entertainment experience. Novus Co-Presidents Doug Holman and Donna Robertson say: “Novus’ pure fiber optic network, combined with its metro Ethernet method of delivering the Internet, is ideal for offering an IP-based TV service. The transition to IPTV will enable Novus to deliver an innovative and personalized HD viewing experience. Novus chose the Inca 4430 transcoder and All Seeing Eye due to the high quality of the management tools, great video quality and the knowledgeable support we’ve experienced both over the phone and in person. These things, combined with our pure fiber optic network, enable the best quality HD digital video for Novus customers.” This new Mediaroom-based TV platform enables Novus to provide a more personal and engaging user experience for residents within multi-dwelling condominium and apartment unit buildings across the Metro Vancouver area. With the ability to deliver high-quality live or on-demand video, Novus customers will be able to continue to customize their television services to suit their needs. To learn more about the Inca 4430 transcoder and 5420 All Seeing Eye product lines, visit: http://www.incanetworks.com About Inca Networks Inca Networks, a WISI company, is reinventing the future of multiscreen video delivery. Inca offers industry-leading Intelligent Video Delivery™, a revolutionary software-centric solution for intelligent, real-time processing of linear and multiscreen television content. At its core is VidiOS™, an advanced software processing and monitoring engine that provides deep visibility and control of all video flows, combined with powerful, modular hardware. Inca’s IP video solutions address all aspects of next-generation video, including high-density MPEG-4 and MPEG-2 HD and SD transcoder modules for linear and multiscreen adaptive bit-rate (ABR) and HTTP live streaming (HLS) services; demultiplexing and remapping of MPTS video from satellite and off-air sources to SPTS streams in digital cable, DSL and fiber to the home (FTTH) IPTV networks; multi-viewer mosaic and status monitoring software, digital music service demuxing, and modular ASI to IP conversion. In July 2015, the Wilhelm Sihn jr. (WISI) company of Germany acquired Vancouver’s Inca Networks Inc. Founded in 1926, WISI is one of the world’s pioneers in broadband reception and distribution technology. Today, WISI’s field of business is the development, production and distribution of products and solutions in the following areas: automotive antenna and cabling, components for broadband networks, fiber optics for broadband, digital signal reception, processing and modulation for TV and radio, in-house multimedia. Inca Networks sells and distributes WISI’s Tangram and Chameleon platforms to the North American, Caribbean and Latin American markets. Video providers around the globe use Inca to easily and affordably deliver content to any screen on any network, all with a superior customer viewing experience and a second-to-none view of the network. http://www.incanetworks.com. Founded in 1996, Novus Entertainment Inc. is a privately owned and operated company providing high-speed Internet, TV, and digital phone services to residents in multi-dwelling units and business customers in Metro Vancouver. Novus continues to expand its fibre optic network throughout Metro Vancouver to offer customers the very best in entertainment and communications technology. The network provides virtually unlimited bandwidth to provide one gigabit per second connectivity and beyond, with the capability to meet future demands, particularly for high-definition and 4K programming. For more information on Novus, go to http://www.novusnow.ca. For more information please contact Rosalinda Thorleifson, Tel. +1-604-418-9715


News Article | November 29, 2016
Site: marketersmedia.com

How the New Administration will React on Recreational vs Medical MIAMI, FL / ACCESSWIRE / November 29, 2016 / Novus Acquisition and Development, Corp. (OTC Markets: NDEV), is a diversified insurance entity in health, liability and excess. Novus is the nation's first healthcare insurance carrier/aggregator in the medical cannabis sector. The day Donald Trump was elected president, four states legalized marijuana for recreational use, while four others legalized or expanded access to medical marijuana. As a result of those ballot initiatives, most states now recognize marijuana as a medicine, and one in five Americans live in a state that has decided to tolerate medical cannabis consumption with a doctor's note. Trump campaigned on a platform of marijuana and legalization, stating; "I think that it should be a state issue, state-by-state," he said to The Washington Post last year. He later told Bill O'Reilly that he is "100 percent" in support of medical marijuana. So as an investor let's asses this situation; Trump is for medical marijuana and no particular stance on recreational, but for the states that just legalized it then the Trump administration would have a monumental cost of fighting this cause state by state, leaving less federal funds to fight the crimes that matter to the American public. While a spending rider that is likely to be renewed protects medical marijuana suppliers from the feds, this rider was approved by Congress in 2014 and 2015 prohibiting the Justice Department from prosecuting marijuana suppliers who "fully comply" with state laws allowing medical use of the plant. A three-judge panel of the U.S. Court of Appeals for the 9th Circuit said federal marijuana defendants are entitled to evidentiary hearings at which they can try to show their actions were authorized by state law. Therefore if Sessions, if given free rein and he is in a marijuana destruction mode he could easily destroy in the recreational industry (not without being challenged) but not the medical marijuana industry. Sessions also could challenge state legalization in federal court. While the DOJ might prevail in arguing that state licensing and regulation of cannabis businesses conflicts with federal law, it cannot force states to re-criminalize on existing businesses, making sense? There are only two Federal Departments that do not uphold against popular vote, they are the DEA and the FDA for obvious reasons, but neither department has regulatory authority over appropriations of funds, Congress does. So, what we have here is most Americans (60 percent, according to Gallup) think marijuana should be legal, while most Republicans continue to oppose legalization federally, and that's ok with businesses in medial marijuana practices, such as Novus' business model. But even among Republicans, most—70 percent, according to CBS News poll conducted last April—think the feds should not try to override state decisions in this area. Again leaving cannabis in recreational realm open for discretion not medical marijuana and any challenges against either one would be an up hill legal battle that can reign for years. Collectively the estimated American voters for marijuana legalization was 160 million and total number of votes Trump and Clinton combined was 124 million votes (chalk this up to the American voters) If Sessions goes rough shot over this issue it will take away from other crimes in America that are more prevalent, again, leaving recreational more venerable and medical marijuana a much safer alternative Trump abiding to his promise to respect state medical marijuana policies could please left-leaning voters in the house and the DOJ. All the president-elect has to do is leave this issue alone. And let both recreational and medical continue to gain market share, which is estimated to be $50 billion by 2020, and tremendous job growth. Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has positioned itself to gain market share within many lines of insurance business within and outside of the MMJ sector. Novus will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient. The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments. For more information, check out: http://www.getnovusnow.com For NDEV 3rd Quarter Financial Filing: http://www.otcmarkets.com/financialReportViewer?symbol=NDEV&id=162770 Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. How the New Administration will React on Recreational vs Medical MIAMI, FL / ACCESSWIRE / November 29, 2016 / Novus Acquisition and Development, Corp. (OTC Markets: NDEV), is a diversified insurance entity in health, liability and excess. Novus is the nation's first healthcare insurance carrier/aggregator in the medical cannabis sector. The day Donald Trump was elected president, four states legalized marijuana for recreational use, while four others legalized or expanded access to medical marijuana. As a result of those ballot initiatives, most states now recognize marijuana as a medicine, and one in five Americans live in a state that has decided to tolerate medical cannabis consumption with a doctor's note. Trump campaigned on a platform of marijuana and legalization, stating; "I think that it should be a state issue, state-by-state," he said to The Washington Post last year. He later told Bill O'Reilly that he is "100 percent" in support of medical marijuana. So as an investor let's asses this situation; Trump is for medical marijuana and no particular stance on recreational, but for the states that just legalized it then the Trump administration would have a monumental cost of fighting this cause state by state, leaving less federal funds to fight the crimes that matter to the American public. While a spending rider that is likely to be renewed protects medical marijuana suppliers from the feds, this rider was approved by Congress in 2014 and 2015 prohibiting the Justice Department from prosecuting marijuana suppliers who "fully comply" with state laws allowing medical use of the plant. A three-judge panel of the U.S. Court of Appeals for the 9th Circuit said federal marijuana defendants are entitled to evidentiary hearings at which they can try to show their actions were authorized by state law. Therefore if Sessions, if given free rein and he is in a marijuana destruction mode he could easily destroy in the recreational industry (not without being challenged) but not the medical marijuana industry. Sessions also could challenge state legalization in federal court. While the DOJ might prevail in arguing that state licensing and regulation of cannabis businesses conflicts with federal law, it cannot force states to re-criminalize on existing businesses, making sense? There are only two Federal Departments that do not uphold against popular vote, they are the DEA and the FDA for obvious reasons, but neither department has regulatory authority over appropriations of funds, Congress does. So, what we have here is most Americans (60 percent, according to Gallup) think marijuana should be legal, while most Republicans continue to oppose legalization federally, and that's ok with businesses in medial marijuana practices, such as Novus' business model. But even among Republicans, most—70 percent, according to CBS News poll conducted last April—think the feds should not try to override state decisions in this area. Again leaving cannabis in recreational realm open for discretion not medical marijuana and any challenges against either one would be an up hill legal battle that can reign for years. Collectively the estimated American voters for marijuana legalization was 160 million and total number of votes Trump and Clinton combined was 124 million votes (chalk this up to the American voters) If Sessions goes rough shot over this issue it will take away from other crimes in America that are more prevalent, again, leaving recreational more venerable and medical marijuana a much safer alternative Trump abiding to his promise to respect state medical marijuana policies could please left-leaning voters in the house and the DOJ. All the president-elect has to do is leave this issue alone. And let both recreational and medical continue to gain market share, which is estimated to be $50 billion by 2020, and tremendous job growth. Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has positioned itself to gain market share within many lines of insurance business within and outside of the MMJ sector. Novus will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient. The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments. For more information, check out: http://www.getnovusnow.com For NDEV 3rd Quarter Financial Filing: http://www.otcmarkets.com/financialReportViewer?symbol=NDEV&id=162770 Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


News Article | November 2, 2016
Site: marketersmedia.com

MIAMI, FL / ACCESSWIRE / November 2, 2016 / Novus Acquisition and Development, Corp. (OTC Markets: NDEV), the nation's first healthcare insurance carrier/aggregator in the medical cannabis sector demonstrates how their MedPlan will capture market share of recreational users and convert them to medical users in California. With the impending approval of Proposition 64 in California, Novus has put into operation, through their insurance subsidiary WCIG Insurance Services, Inc., a supplemental Workers Compensation Program that will include medical marijuana for patients in the State of California. How the MedPlan was derived was based on the Workers' Compensation Insurance Rating Bureau's Actuarial assessment, that workers' compensation premiums in California continue to grow at double-digit rates. The state's workers' comp written premium accounts for more than a quarter of the U.S. total, but only 12 percent of America's workforce, according to the report. Additionally, to make matters worse, the California coverage compares poorly with the rest of the nation How does California's workers' comp and Novus' supplemental medical marijuana insurance coverage benefit patient and employers interests? Four principal factors: a) California has the highest permanent disability claims in the nation with an inherent on going pain management crisis, b) the state has among the highest claims in terms of medical costs, c) it has a high cost of delivering insurance benefits and; d) another driver of California's higher premiums is the state's medical treatment costs. How we approached solving the problem is by implementing a supplemental workers compensation program with Novus' infrastructure with California marijuana dispensaries. Then instrumentally delivering a supplemental worker's compensation plan will ease insurers and employers burdens by allowing Novus to procure, in network, a consortia of physicians that will take in patients, generate more medical marijuana recommendations for the protocol for pain management and other aliments to ease suffering. What makes this of value for insurers and employers is that California worker's compensation premiums will decrease losses because medical marijuana and Novus premiums are affordable. Once the ballot initiatives in California is approved under Proposition 64 Novus will take advantage of three areas a) the abatement of taxation for medical marijuana cardholders b) many doctors are approving medical cannabis and writing recommendation forms for patients because of, c) the opioids crisis, many California doctors are writing less prescriptions for opioids and combining it with medical cannabis for pain management. The end result will be that Novus will get an increase in patient/member signups from the overlapping of recreational users that become medical users under this program. The graphic below shows the percentile range and the overlying of cannabis users in medical (33%) versus recreation (55%) users, coinciding with worker's comp claims, which is estimated at 12%. Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has positioned itself to gain market share within many lines of insurance business within and outside of the MMJ sector. Novus will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient. The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments. For more information, check out: http://www.getnovusnow.com For NDEV 2nd Quarter Financial Filing: http://bit.ly/2cJ3Efj Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. MIAMI, FL / ACCESSWIRE / November 2, 2016 / Novus Acquisition and Development, Corp. (OTC Markets: NDEV), the nation's first healthcare insurance carrier/aggregator in the medical cannabis sector demonstrates how their MedPlan will capture market share of recreational users and convert them to medical users in California. With the impending approval of Proposition 64 in California, Novus has put into operation, through their insurance subsidiary WCIG Insurance Services, Inc., a supplemental Workers Compensation Program that will include medical marijuana for patients in the State of California. How the MedPlan was derived was based on the Workers' Compensation Insurance Rating Bureau's Actuarial assessment, that workers' compensation premiums in California continue to grow at double-digit rates. The state's workers' comp written premium accounts for more than a quarter of the U.S. total, but only 12 percent of America's workforce, according to the report. Additionally, to make matters worse, the California coverage compares poorly with the rest of the nation How does California's workers' comp and Novus' supplemental medical marijuana insurance coverage benefit patient and employers interests? Four principal factors: a) California has the highest permanent disability claims in the nation with an inherent on going pain management crisis, b) the state has among the highest claims in terms of medical costs, c) it has a high cost of delivering insurance benefits and; d) another driver of California's higher premiums is the state's medical treatment costs. How we approached solving the problem is by implementing a supplemental workers compensation program with Novus' infrastructure with California marijuana dispensaries. Then instrumentally delivering a supplemental worker's compensation plan will ease insurers and employers burdens by allowing Novus to procure, in network, a consortia of physicians that will take in patients, generate more medical marijuana recommendations for the protocol for pain management and other aliments to ease suffering. What makes this of value for insurers and employers is that California worker's compensation premiums will decrease losses because medical marijuana and Novus premiums are affordable. Once the ballot initiatives in California is approved under Proposition 64 Novus will take advantage of three areas a) the abatement of taxation for medical marijuana cardholders b) many doctors are approving medical cannabis and writing recommendation forms for patients because of, c) the opioids crisis, many California doctors are writing less prescriptions for opioids and combining it with medical cannabis for pain management. The end result will be that Novus will get an increase in patient/member signups from the overlapping of recreational users that become medical users under this program. The graphic below shows the percentile range and the overlying of cannabis users in medical (33%) versus recreation (55%) users, coinciding with worker's comp claims, which is estimated at 12%. Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has positioned itself to gain market share within many lines of insurance business within and outside of the MMJ sector. Novus will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient. The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments. For more information, check out: http://www.getnovusnow.com For NDEV 2nd Quarter Financial Filing: http://bit.ly/2cJ3Efj Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


NEW YORK--(BUSINESS WIRE)--Novus, the world’s leading Portfolio Intelligence platform for institutional investors and managers, and Cheyne Capital Management LLP (Cheyne), the London-based global alternative investment manager, announced today that they have entered into a partnership to build an innovative fixed-income analytics platform for both allocators and managers within the investment community. The platform will harness the power of Novus’ robust data alongside Cheyne’s extensive credit investing expertise to provide risk-based analytics and portfolio insights typically not widely available in fixed income, to improve investment skills, portfolio optimisation and performance potential. The Credit team at Cheyne Capital will work closely with Novus’ engineers and data scientists to help inform and shape key product decisions to create this cutting-edge platform for institutional allocators and managers. Together, the partnership will look to contribute to the growing understanding of factor investing in credit markets. It will also assist Cheyne in advancing its own skillset and support Novus in expanding its analytics offering across the fixed income asset class, a field whose complexity has often confounded the provision of in-depth analytics. “Novus has made an impressive impact on the asset management industry by equipping both allocators and asset managers with insights and tools to better understand, measure and improve portfolio construction,” said Stuart Fiertz, Cheyne Capital’s co-founder, President and Director of Research. “At Cheyne, our priority is to consistently deliver value for our clients and the ability to have a strong understanding of both markets and positions, and glean insights accordingly is essential to achieving this. We see a growing opportunity for alternative asset managers and FinTech companies to work together to help propel our industry forward and provide higher-quality intelligence to allocators to improve processes for selecting investments and managers.” Andrea Gentilini, Head of Europe for Novus added: “Novus is committed to designing and building a world-class fixed-income analytics platform for the investor community. The company is investing a substantial amount of its technology and engineering resources into creating a fully deployable product that satisfies the market demand for better, more accurate and predictive fixed income analytics.” “By constructing a team of cutting-edge data scientists, credit analytics specialists and industry practitioners, Cheyne has become one of the most experienced and knowledgeable fixed-income experts. We are excited to work with Cheyne to build this platform, which will span research and portfolio management across the credit sector, and help to accelerate the development of Portfolio Intelligence in the broader investment community.” To learn more about the Novus Alpha Platform, please visit: https://www.novus.com/. Founded in 2007, Novus is the world’s leading Portfolio Intelligence Platform for institutional investors. We merge big data, analytics, and professional services to help investment managers and allocators operate more efficiently, discover key portfolio insights, and achieve their investment goals. Clients managing over $3 trillion dollars in assets rely on our products and services to help them make better investment decisions. Based out of New York, with offices in London, Zurich, Boston, and Chicago, Novus serves the global investment management community. Launched in 2000, Cheyne Capital is one of Europe’s leading alternative investment managers. Cheyne invests across the capital structure from the senior debt to the equity of corporates and real estate. With an investment philosophy grounded in rigorous fundamental analysis, the firm's main areas of expertise are: Real Estate Debt, Social Property Impact, Corporate Credit, Convertible Bonds, Event Driven and Equities. Cheyne Capital Management (U.K.) LLP is authorised and regulated in the U.K. by the Financial Conduct Authority, and registered as an Investment Adviser in the U.S. by the Securities and Exchange Commission.


Patent
Novus Inc | Date: 2013-11-05

A system, method, and computer program product for modeling a risk are provided. An equalizer and an equalizer backend model portfolio risk based on a scenario generated by the equalizer. A scenario includes an active factor, a passive factor, and a change in an active factor level. To model portfolio risk, the equalizer backend uses two-tiered regression analysis. In the first regression, the equalizer backend regresses the passive factor against the active factor and determines changes in a passive factor level. In the second regression, the equalizer backend regresses the changes in the passive and active factor levels against positions in the portfolio that models portfolio risk. The equalizer displays the modeled portfolio risk.


News Article | November 16, 2016
Site: marketersmedia.com

Quarterly Report Show Increase Revenues and Improved Balance Sheet Key Business Milestones Achieved in Coverage and Marketing Well Positioned for Growth in 2017 MIAMI, FL / ACCESSWIRE / November 16, 2016 / Novus Acquisition and Development, Corp. (OTC Markets: NDEV), the nation's first healthcare insurance carrier/aggregator in the medical cannabis sector, today announced its third quarter results for the period ended September 30, 2016. The culmination of five years of hard work, laying the groundwork and $7 million of paid-in capital has fortified the company's infrastructure and positioning and has led to many milestones being achieved in the quarter. Novus through its wholly owned subsidiary WCIG Insurance Service, Inc., is a California insurance brokerage entity. Novus initiated its insurance business model within the medical marijuana space where it can render risk and non-risk insurance models in Washington, Oregon, Hawaii, Michigan, Arizona, Colorado, California, Washington, and Vermont to sell benefits packages in addition to medical marijuana CBD concentrate, dental, vision, diabetic supplies, prescriptions, hearing, and other integrative medicines. The Novus provider network has taken some time to build out in having either contracted or contracts pending with over 100+ dispensaries to participate in our insurance network. Chief Executive Officer Frank Labrozzi, stated, "It has taken a year to build the insurance regulatory and technological infrastructure to operate as a medical marijuana health plan. Since we entered into this space, we have had difficulties in getting our branding out through traditional advertising segments. However, we now have approvals to allow our marketing and advertising to be disseminated through digital ad exchanges, unabated. Therefore, we can launch aggressive marketing campaigns. Despite the impediments that are inherent to the cannabis space, we are still achieving our goals." Revenues increased 35% with net profit of 54% Improved balance sheet; increased cash balance to $60,000 and NAV to $1.25 million Increased coverage included the entire states of California and Arizona Introduction of worker compensation package to capture market share in the recreational space Success in social networking Identified digital marketing breakthroughs with a strategy to execute going forward Financial Overview: Revenue increased by 35% for the three months ended September 30, 2016, from the second quarter of 2016. The balance sheet improved with the cash balance increasing to $60,000 and the Net Asset Value increasing by 25% from $1,052,594 to $1,252,585. The company is starting to see that banks are more willing to take deposits on companies that do not handle the cannabis plant as opposed to 2015 and earlier in 2016. And, we are beginning to see our cash flow improve by 100% simply due to implementing in-house marketing program. Coverage: Completion of covering the entire states of California and Arizona, equating to 57% of the entire cannabis market. Worker Compensation Package: We have begun a Worker's Comp package in California to allow us to give cannabis related products to injured workers, allowing Novus to capture a portion of recreational users. Overcoming Marketing and Advertising Impediments: Each state has their own rules and regulations on marketing and advertising relating to cannabis related meds and products. To make matters more difficult medians such radio, television and digital advertising (Social Networking, Google Adwords, Pay Per Click, Pay Per Acquisition) have rejected by these Internet giants. The company has utilized many third party marketers to brand and patient procurement, only resulting in high Return on Investment (ROI) or lack of performance all together by the third party vendors. This prompted to bring our marketing initiatives in-house and hire the right assets to implement them. A direct result in our 100% increase of cash flow. Social Networking Success: Digital ad dissemination on Twitter, Facebook and LinkedIn has given us much needed branding and lead generation. Since August the company has gone from 10,000 impressions to 400,000 impressions per month with a 1% engagement rate to our sales funnel, an increase of over 4,000% at a fraction of the cost for third party marketers. Our projected estimate by year-end is that we will be able to triple that by getting approximately 1,000,000 monthly unique views to our digital ads. Digital Ad Dissemination with Ad Exchanges: Ad exchanges with their technology platforms facilitate the buying and selling of media advertising inventory from multiple ad networks. The approach is algorithmic technology-driven as opposed to the historical approach of negotiating price on media. Data is produced in real time by Nielsen that geo targets consumers that have engaged in certain behavioral activities on the Internet. There are 50 notable digital ad exchanges of which we have identified 10 exchanges that will allow advertising that contain the word "marijuana" and/or "cannabis." It is our determination that this will be a game changer not only for Novus but also for the medical cannabis industry as a whole. Programmatic Marketing Proximity Targeting: This technology helps our marketing efforts reach demographic audiences down to the proximity of our target consumer. This is the best utilization of quality data that can identify our target audience down to every storefront, venue within our target audience. For example, since we can target consumers via categories like if they visit pain clinics and capture their information on either mobile or desktop devices, or reach consumers when they are at a dispensary and send an opt-in advertisement about Novus. This precision targeting is done by gathering accurate data from Factual, similar to Google Maps but allows closer proximity than Google Maps and a customizable location based, geo-fencing, and consumer activity via app on mobile devices down to 1 meter. This quick video proximity marketing will surely convince you that Novus is taking the right route towards their marketing effort: https://vimeo.com/120834432. Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has positioned itself to gain market share within many lines of insurance business within and outside of the MMJ sector. Novus will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient. The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments. For more information, check out: http://www.getnovusnow.com For NDEV 3rd Quarter Financial Filing: http://www.otcmarkets.com/financialReportViewer?symbol=NDEV&id=162770 Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Quarterly Report Show Increase Revenues and Improved Balance Sheet Key Business Milestones Achieved in Coverage and Marketing Well Positioned for Growth in 2017 MIAMI, FL / ACCESSWIRE / November 16, 2016 / Novus Acquisition and Development, Corp. (OTC Markets: NDEV), the nation's first healthcare insurance carrier/aggregator in the medical cannabis sector, today announced its third quarter results for the period ended September 30, 2016. The culmination of five years of hard work, laying the groundwork and $7 million of paid-in capital has fortified the company's infrastructure and positioning and has led to many milestones being achieved in the quarter. Novus through its wholly owned subsidiary WCIG Insurance Service, Inc., is a California insurance brokerage entity. Novus initiated its insurance business model within the medical marijuana space where it can render risk and non-risk insurance models in Washington, Oregon, Hawaii, Michigan, Arizona, Colorado, California, Washington, and Vermont to sell benefits packages in addition to medical marijuana CBD concentrate, dental, vision, diabetic supplies, prescriptions, hearing, and other integrative medicines. The Novus provider network has taken some time to build out in having either contracted or contracts pending with over 100+ dispensaries to participate in our insurance network. Chief Executive Officer Frank Labrozzi, stated, "It has taken a year to build the insurance regulatory and technological infrastructure to operate as a medical marijuana health plan. Since we entered into this space, we have had difficulties in getting our branding out through traditional advertising segments. However, we now have approvals to allow our marketing and advertising to be disseminated through digital ad exchanges, unabated. Therefore, we can launch aggressive marketing campaigns. Despite the impediments that are inherent to the cannabis space, we are still achieving our goals." Revenues increased 35% with net profit of 54% Improved balance sheet; increased cash balance to $60,000 and NAV to $1.25 million Increased coverage included the entire states of California and Arizona Introduction of worker compensation package to capture market share in the recreational space Success in social networking Identified digital marketing breakthroughs with a strategy to execute going forward Financial Overview: Revenue increased by 35% for the three months ended September 30, 2016, from the second quarter of 2016. The balance sheet improved with the cash balance increasing to $60,000 and the Net Asset Value increasing by 25% from $1,052,594 to $1,252,585. The company is starting to see that banks are more willing to take deposits on companies that do not handle the cannabis plant as opposed to 2015 and earlier in 2016. And, we are beginning to see our cash flow improve by 100% simply due to implementing in-house marketing program. Coverage: Completion of covering the entire states of California and Arizona, equating to 57% of the entire cannabis market. Worker Compensation Package: We have begun a Worker's Comp package in California to allow us to give cannabis related products to injured workers, allowing Novus to capture a portion of recreational users. Overcoming Marketing and Advertising Impediments: Each state has their own rules and regulations on marketing and advertising relating to cannabis related meds and products. To make matters more difficult medians such radio, television and digital advertising (Social Networking, Google Adwords, Pay Per Click, Pay Per Acquisition) have rejected by these Internet giants. The company has utilized many third party marketers to brand and patient procurement, only resulting in high Return on Investment (ROI) or lack of performance all together by the third party vendors. This prompted to bring our marketing initiatives in-house and hire the right assets to implement them. A direct result in our 100% increase of cash flow. Social Networking Success: Digital ad dissemination on Twitter, Facebook and LinkedIn has given us much needed branding and lead generation. Since August the company has gone from 10,000 impressions to 400,000 impressions per month with a 1% engagement rate to our sales funnel, an increase of over 4,000% at a fraction of the cost for third party marketers. Our projected estimate by year-end is that we will be able to triple that by getting approximately 1,000,000 monthly unique views to our digital ads. Digital Ad Dissemination with Ad Exchanges: Ad exchanges with their technology platforms facilitate the buying and selling of media advertising inventory from multiple ad networks. The approach is algorithmic technology-driven as opposed to the historical approach of negotiating price on media. Data is produced in real time by Nielsen that geo targets consumers that have engaged in certain behavioral activities on the Internet. There are 50 notable digital ad exchanges of which we have identified 10 exchanges that will allow advertising that contain the word "marijuana" and/or "cannabis." It is our determination that this will be a game changer not only for Novus but also for the medical cannabis industry as a whole. Programmatic Marketing Proximity Targeting: This technology helps our marketing efforts reach demographic audiences down to the proximity of our target consumer. This is the best utilization of quality data that can identify our target audience down to every storefront, venue within our target audience. For example, since we can target consumers via categories like if they visit pain clinics and capture their information on either mobile or desktop devices, or reach consumers when they are at a dispensary and send an opt-in advertisement about Novus. This precision targeting is done by gathering accurate data from Factual, similar to Google Maps but allows closer proximity than Google Maps and a customizable location based, geo-fencing, and consumer activity via app on mobile devices down to 1 meter. This quick video proximity marketing will surely convince you that Novus is taking the right route towards their marketing effort: https://vimeo.com/120834432. Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has positioned itself to gain market share within many lines of insurance business within and outside of the MMJ sector. Novus will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient. The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments. For more information, check out: http://www.getnovusnow.com For NDEV 3rd Quarter Financial Filing: http://www.otcmarkets.com/financialReportViewer?symbol=NDEV&id=162770 Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


News Article | October 5, 2015
Site: www.ibtimes.com

With the September jobless figures behind them and no interest-rate hike immediately ahead of them, investors this week likely will be anticipating the release Thursday of the minutes of the Federal Open Markets Committee (FOMC) meeting last month, looking for the reasons why the U.S. Federal Reserve again delayed the first increase in its federal funds rate in almost a decade. Also making investors nervous is whether Congress will produce a budget or engage in the brinkmanship that resulted in a downgrade of the U.S. credit rating two years ago. President Barack Obama signaled in his weekly radio address Saturday he does not support any more stopgap measures. Congress put a Band-Aid on the budget process last week by approving a continuing resolution that runs out in December. In addition to the FOMC minutes, investors in the American markets likely will be scrutinizing this week the September Institute for Supply Management nonmanufacturing report, as well as figures on the country’s consumer credit, import prices, trade deficit and wholesale inventories. Numbers on home sales will come out the following week. Last month's results wrapped up the worst quarter since 2011, and investors expect the downward trajectory to continue, Reuters reported. The focus is expected to turn to quarterly earnings reports and Alcoa (NYSE:AA) traditionally kicks off the festivities. It's scheduled to report Thursday. Among the firms announcing quarterly financial results Monday are Bankrate Inc. (NYSE:RATE), Cogent Communications Holdings Inc. (NASDAQ:CCOI) and Container Store Group Inc. (NYSE:TCS). With all that in mind, Asian stocks opened higher, with the Japanese Nikkei adding more than 1 percent and Hong Kong's Heng Seng adding nearly 2 percent. China's Shanghai Composite was closed for a holiday. Traders are anticipating this week the release of the minutes of the last meeting of the Federal Open Market Committee. Above, an employee views trading screens at the London offices of Panmure Gordon and Co. Oct. 20, 2014.  Carl Court/Getty Images Federal Reserve Chair Janet Yellen has been signaling for many months an interest-rate hike is in the offing. As things stand, with the federal funds rate already at rock-bottom, the Fed appears to have no wiggle room should the economy take a dive. Adam Posen, president of the Peterson Institute for International Economics, said at a conference hosted by the Federal Reserve Bank of Boston last week there is nothing that can be done to forestall another financial crisis. “The current U.S. institutional setup is likely to fail in a crisis, and will be doing less to prevent a crisis than it should be,” Posen said. He added that the current regulatory structure is a “mess,” MarketWatch reported. Former Fed Vice Chairman Donald Kohn agreed there are deficiencies in the system, describing it as “balkanized,” and current Fed Vice Chairman Stanley Fischer said the American central bank needs new tools to prevent another bubble in the real-estate sector. According to Boston Fed President Eric Rosengren, what is lacking is a mandate from Congress giving the Fed the ability to promote financial stability. Federal Reserve Bank of New York President William Dudley told the meeting the financial system has been made "more resilient to shocks," Morningstar reported. But, he said, regulators are a long way from " being able to successfully use [macroprudential] tools" to deal with financial imbalances. U.S. hedge funds could see their worst year since the 2008 financial crisis, triggered by the fall-off in the biotechnology and health-care sectors, Reuters reported. “Hedge funds are reeling from a relentless rout that has all but killed a year’s worth of alpha in a matter of two weeks,” Stanley Altshuller, founding partner at research firm Novus, wrote in a report. Alpha is a risk-adjusted gauge measuring an investment’s performance in comparison with a benchmark, commonly a market index such as the S&P 500 (INDEXSP:.INX). Friday’s employment report, showing the American economy created only 142,000 jobs in September, was largely discounted by U.S. equity traders, but it sent the Bloomberg Dollar Spot Index to a two-week low, the beginning of a depreciation that could prevent a December interest-rate rise. “I’m struggling to find anything positive out of this -- the dollar selling is probably going to continue,” Pete Karabatos, a senior foreign-exchange trader at Silicon Valley Bank in Santa Clara, California, told Bloomberg News.


News Article | April 22, 2015
Site: www.prweb.com

Novus, a portfolio analytics and intelligence platform that helps institutional investors analyze their portfolios, today announced the release of their updated European Short Observer, a free interactive tool that allows users to monitor and analyze short selling trends in Europe. This tool is updated every month with the latest holdings information. Novus has compiled all public data from short disclosure filings in Europe and presented it in a new visualization. Investors and managers can analyze the relative sizes, distributions, and crowding in public short positions for managers engaged in short selling in Europe. The interactive graphic allows users to isolate a manager and identify their public shorts, trace other funds shorting the same security, or reverse the analysis and start from the security. "The European Short Observer lets investors get a detailed view of hedge fund managers' short exposure to Europe," says Stan Altshuller, Chief Research Officer at Novus. "Are your managers shorting for alpha or beta? Are they finding unique short opportunities or playing in more common shorts? Managers themselves can take advantage of the tool for short idea generation, understanding how crowded their shorts are, and how much short squeeze risk exists. In addition, managers can get a good grasp of who is on the other side of their European long positions." To view the Interactive Short Observer, please visit: http://bit.ly/1J6On2u For Stan Altshuller's insights into Q1 European shorting, please read his article: http://bit.ly/1K2e5mk To learn more about Novus, please visit: http://www.novus.com *** Novus was founded in 2007 by a group of investors, data scientists and engineers to build a portfolio analytics and intelligence platform for institutional investors. Today, the platform is used by some of the top hedge funds, fund of funds, pensions & endowments, and sovereign wealth funds to analyze their risk, performance, and attribution. Portfolio managers, investor relations and operations teams use the Novus Platform in different ways, but most use the platform to analyze and manage their risks, report to their investors, and ultimately generate more alpha with better portfolio intelligence. Through the firm's data-driven approach, industry-leading analytics and unique team of ex-portfolio managers and investors, Novus is transforming the way the world invests. Novus is based in New York, with offices in San Francisco, California and Zurich, Switzerland. For more information, visit http://www.novus.com.


News Article | December 27, 2016
Site: www.prnewswire.com

PEMBROKE PINES, Fla., Dec. 27, 2016 /PRNewswire/ -- Novus Inc., an exclusive shoe store company and renowned Puerto Rican brand announces its arrival in the American market. With over 40 years of experience and 60 stores in Puerto Rico, Novus is expanding to the United States where,...

Loading Novus Inc collaborators
Loading Novus Inc collaborators